Literature DB >> 25949884

BRAF-inhibition and tumor immune suppression.

Shannon M Steinberg1, Mary Jo Turk2.   

Abstract

As BRAFV600E-inhibitors become standard treatment for many metastatic melanoma patients, research has begun to elucidate their impact on the tumor immune landscape. Here, we highlight our recent studies demonstrating the ability of melanoma cell-intrinsic BRAFV600E-inhibition to selectively reduce intratumoral immunosuppressive cell populations and enhance antitumor CD8+ T-cell immunity.

Entities:  

Keywords:  BRAF; CD8 T cells; MDSC, myeloid-derived suppressor cell; TME, tumor microenvironment; Treg, regulatory T cell; melanoma; myeloid-derived suppressor cells; regulatory T cells

Year:  2015        PMID： 25949884      PMCID： PMC4404921          DOI： 10.4161/2162402X.2014.988039

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

Authors:  Axel Hauschild; Jean-Jacques Grob; Lev V Demidov; Thomas Jouary; Ralf Gutzmer; Michael Millward; Piotr Rutkowski; Christian U Blank; Wilson H Miller; Eckhart Kaempgen; Salvador Martín-Algarra; Boguslawa Karaszewska; Cornelia Mauch; Vanna Chiarion-Sileni; Anne-Marie Martin; Suzanne Swann; Patricia Haney; Beloo Mirakhur; Mary E Guckert; Vicki Goodman; Paul B Chapman
Journal:  Lancet       Date:  2012-06-25       Impact factor: 79.321

2.  BRAF inhibition alleviates immune suppression in murine autochthonous melanoma.

Authors:  Shannon M Steinberg; Peisheng Zhang; Brian T Malik; Andrea Boni; Tamer B Shabaneh; Katelyn T Byrne; David W Mullins; Constance E Brinckerhoff; Marc S Ernstoff; Marcus W Bosenberg; Mary Jo Turk
Journal:  Cancer Immunol Res       Date:  2014-09-02       Impact factor: 11.151

3.  Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.

Authors:  Zachary A Cooper; Vikram R Juneja; Peter T Sage; Dennie T Frederick; Adriano Piris; Devarati Mitra; Jennifer A Lo; F Stephen Hodi; Gordon J Freeman; Marcus W Bosenberg; Martin McMahon; Keith T Flaherty; David E Fisher; Arlene H Sharpe; Jennifer A Wargo
Journal:  Cancer Immunol Res       Date:  2014-04-29       Impact factor: 11.151

4.  Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.

Authors:  James S Wilmott; Georgina V Long; Julie R Howle; Lauren E Haydu; Raghwa N Sharma; John F Thompson; Richard F Kefford; Peter Hersey; Richard A Scolyer
Journal:  Clin Cancer Res       Date:  2011-12-12       Impact factor: 12.531

5.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

6.  Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Authors:  Deborah A Knight; Shin Foong Ngiow; Ming Li; Tiffany Parmenter; Stephen Mok; Ashley Cass; Nicole M Haynes; Kathryn Kinross; Hideo Yagita; Richard C Koya; Thomas G Graeber; Antoni Ribas; Grant A McArthur; Mark J Smyth
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

7.  Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ.

Authors:  Ping-Chih Ho; Katrina M Meeth; Yao-Chen Tsui; Bhaskar Srivastava; Marcus W Bosenberg; Susan M Kaech
Journal:  Cancer Res       Date:  2014-04-15       Impact factor: 12.701

8.  Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.

Authors:  Meghna Das Thakur; Fernando Salangsang; Allison S Landman; William R Sellers; Nancy K Pryer; Mitchell P Levesque; Reinhard Dummer; Martin McMahon; Darrin D Stuart
Journal:  Nature       Date:  2013-01-09       Impact factor: 49.962

9.  Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma.

Authors:  Anna Hooijkaas; Jules Gadiot; Michelle Morrow; Ross Stewart; Ton Schumacher; Christian U Blank
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110

10.  Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.

Authors:  David Dankort; David P Curley; Robert A Cartlidge; Betsy Nelson; Anthony N Karnezis; William E Damsky; Mingjian J You; Ronald A DePinho; Martin McMahon; Marcus Bosenberg
Journal:  Nat Genet       Date:  2009-03-12       Impact factor: 38.330
  10 in total
  5 in total

Review 1.  Molecular mechanisms of flavonoids in melanin synthesis and the potential for the prevention and treatment of melanoma.

Authors:  Feng Liu-Smith; Frank L Meyskens
Journal:  Mol Nutr Food Res       Date:  2016-03-21       Impact factor: 5.914

2.  Cutaneous sarcoidosis due to immune-checkpoint inhibition and exacerbated by a novel BRAF dimerization inhibitor.

Authors:  J P Pham; P Star; S Wong; D L Damian; R P M Saw; M J Whitfeld; A M Menzies; A M Joshua; A Smith
Journal:  Skin Health Dis       Date:  2021-10-20

Review 3.  Immune system and melanoma biology: a balance between immunosurveillance and immune escape.

Authors:  Anna Passarelli; Francesco Mannavola; Luigia Stefania Stucci; Marco Tucci; Francesco Silvestris
Journal:  Oncotarget       Date:  2017-10-31

4.  Profiling networks of distinct immune-cells in tumors.

Authors:  Trevor Clancy; Eivind Hovig
Journal:  BMC Bioinformatics       Date:  2016-07-04       Impact factor: 3.169

Review 5.  Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells.

Authors:  Marco Tucci; Anna Passarelli; Francesco Mannavola; Claudia Felici; Luigia Stefania Stucci; Mauro Cives; Francesco Silvestris
Journal:  Front Oncol       Date:  2019-11-05       Impact factor: 6.244
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.